<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02213497</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 01214</org_study_id>
    <nct_id>NCT02213497</nct_id>
  </id_info>
  <brief_title>Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer</brief_title>
  <official_title>Phase I Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with esophageal cancer to be treated with concurrent preoperative proton therapy
      along with carboplatin and paclitaxel.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Esophageal Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>18F-FDG (Fluorodeoxyglucose) PET</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a histologic diagnosis of adenocarcinoma of the esophagus located distal
             to the carina

          -  Patients with AJCC 7th edition clinical stage IIB-IIIC

          -  Patient must be &gt;18 years of age.

          -  Patients must have an ECOG Performance Status of 0-1

          -  Patients must be able to provide informed consent.

          -  Patients must be surgical candidates with adequate hematologic, renal, hepatic and
             pulmonary function

          -  serum AST and ALT &lt; 2 times the upper limit of normal

          -  Patients must have bilirubin &lt; 1.5 Ã— normal.

          -  WBC &gt; 3000/mm3, platelets &gt; 100,000 mm3.

          -  Hemoglobin &gt; 10 g/dL serum creatinine &lt; 1.5 times the upper limit of normal

          -  Women of child-bearing potential as long as she agrees to use a recognized method of
             birth control (e.g. oral contraceptive, IUD, condoms or other barrier methods etc.).
             Hysterectomy or menopause must be clinically documented.

        Exclusion Criteria:

          -  Patients with primary tumors exceeding 8 cm in length or 5 cm in width ( length should
             be measured by endoscopic findings, width should be measured by diagnostic CT or CT
             portion of PET/CT)

          -  Patients with primary tumors located at or above the carina

          -  Prior or simultaneous malignancies within the past two years (other than cutaneous
             squamous or basal cell carcinoma, melanoma in situ or thyroid carcinoma)

          -  Pregnant women, women planning to become pregnant and women that are nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Plastaras, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Plastaras, MD</last_name>
    <phone>855-216-0098</phone>
    <email>PennCancerTrials@emergingmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Plastaras, MD</last_name>
      <phone>855-216-0098</phone>
      <email>PennCancerTrials@emergingmed.com</email>
    </contact>
    <investigator>
      <last_name>John Plastaras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2014</study_first_submitted>
  <study_first_submitted_qc>August 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2014</study_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patients with esophageal cancer to be treated with concurrent preoperative chemoradiation with carboplatin and paclitaxel.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

